Journal of Clinical and Experimental Hematology

Original Research Open Access

Neutropenia in myelosuppressed cancer patients treated with recombinant human erythropoietin (EPO) 

Daniel G. Wright , Elizabeth C. Wright , Constance T. Noguchi

Recombinant human erythropoietin (EPO) has been used extensively for over 3 decades to treat anemia, including that associated with cancer treatment. Multiple randomized clinical trials have found that EPO treatment ameliorates anemia and reduces transfusion requirements in cancer patients undergoing chemotherapy. 

J Clin Exp Hematol, 2026, Volume 5, Issue 1, p6-12 | DOI: 10.46439/hematol.5.034